1476 results about "Nucleic acid sequence" patented technology

The invention discloses application of a GsRZ1A gene in improving alkali resistance of plants, and belongs to the technical field of genetic engineering. The nucleotide sequence of the GsRZ1A gene is as shown in SEQ ID NO: 1, and the coded amino acid sequence of the GsRZ1A gene is as shown in SEQ ID NO: 2. A transgenic line is obtained by constructing an overexpression vector of the GsRZ1A gene and transforming soybeans. A transgenic line is subjected to alkali stress treatment, and a result shows that the overexpressed GsRZ1A soybean line shows a faster relative growth rate, the total leaf area, the leaf chlorophyll content and the relative water content are all higher than those of a control line of an empty vector, the total root length and the total root surface area of a root system are also remarkably larger than those of a control group, and the antioxidant enzyme activity can be improved; the accumulation of superoxide anions and malonaldehyde is reduced, and the accumulation of osmotic regulation substances such as soluble sugar is increased to enhance the tolerance of the soybeans to alkali stress, so that the method has an important application prospect in alkali-resistant plant breeding.

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.

Methods, systems, and software for estimating circulating tumor fraction are provided. A first plurality of nucleic acid sequences for a plurality of loci in genomic DNA from a solid tumor sample is obtained. A second plurality of nucleic acid sequences for a plurality of cell-free DNA fragments obtained from a liquid biopsy sample from the same subject is obtained. One or more somatic mutations is identified in the first plurality of nucleic acid sequences. A variant allele frequency (VAF) is determined for each somatic mutation based on a frequency of the respective somatic mutation in the liquid biopsy sample and a frequency of the corresponding wild type allele in the liquid biopsy sample, thereby determining a set of VAFs. An estimate of the circulating tumor fraction for the test subject is determined based on the set of VAFs for the one or more somatic mutations.

The invention discloses an oil palm U6 promoter gene and application thereof, and belongs to the technical field of biology. The nucleotide sequence of the promoter gene is shown as SEQ ID NO.1. The oil palm RNA polymerase III type promoter gene, namely the oil palm endogenous U6 promoter gene EgU6, is obtained by cloning in an oil palm genome for the first time, and the promoter gene has high transcriptional activity and can drive downstream fluorescent protein mNeonGreen expression. The candidate oil palm endogenous U6 promoter gene can be provided for subsequently establishing a high-efficiency oil palm gene editing technology system based on a CRISPR / cas9 (Clustered Regularly Interspaced Short Palindromic Repeats / Cas9) system.

The invention discloses keratinase Phyto-Keratinase and application of the keratinase Phyto-Keratinase. The keratinase Phyto-Keratinase comprises the following components: (1) protease which is coded by a nucleotide sequence as shown in SEQ ID NO.1; and / or (2) protease which is derived from bacillus subtilis, is coded by a nucleic acid sequence with more than 98% of identity with the SEQ ID NO.1 nucleotide sequence and has the characteristic of hydrolyzing keratin. According to the plant keratinase Phyto-Keratinase disclosed by the invention, the Phyto-Keratinase (plant keratinase) produced by utilizing microbial fermentation is a serine proteolytic enzyme, is also a biocompatible cutinase, and is obtained by fermenting saccharomyces cerevisiae. Phyto-Keratinase provides a nitrogen source for the growth of plants (beans), and contains various amino acids (functional peptides) and special proteolytic enzymes derived from the plants at the same time. The Phyto-keratinase can provide the effects of resisting inflammation, removing cutin and providing nutrition for skin regeneration at the same time, can relieve various inflammations by inhibiting PAR-2 receptors, and has potential value in the fields of cosmetics, beauty medicine and environment.

The present disclosure relates to methods for the production of a cell-based product based on using synthetic promoters or a cellular input-output unit thereof, configured for controlling the expression of at least one nucleic acid sequence of interest, upon sensing dynamic cellular- and / or environmental- state and / or condition, that leads to a desired phenotype of the cells. The present disclosure further provides cell-based products, in particular, animal cell-based meat products (ACBM).

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The present disclosure provides compositions and methods for prime editing with improved editing efficiency and / or reduced indel formation by inhibiting the DNA mismatch repair path way while conducting prime editing of a target site. Accordingly, the present disclosure provides a method for editing a nucleic acid molecule by prime editing that involves contacting a nucleic acid molecule with a prime editor, a pegRNA, and an inhibitor of the DNA mismatch repair pathway, thereby installing one or more modifications to the nucleic acid molecule at a target site with increased editing efficiency and / or lower indel formation. The present disclosure further provides polynucleotides for editing a DNA target site by prime editing comprising a nucleic acid sequence encoding a napDNAbp, a polymerase, and an inhibitor of the DNA mismatch repair pathway, wherein the napDNAbp and polymerase is capable in the presence of a pegRNA of installing one or more modifications in the DNA target site with increased editing efficiency and / or lower indel formation. The disclosure further provides, vectors, cells, and kits comprising the compositions and polynucleotides of the disclosure. The present disclosure also provides compositions and methods for prime editing with improved editing efficiency and / or reduced indel formation with modified prime editor fusion proteins. The disclosure further provides, vectors, cells, and kits comprising the compositions and polynucleotides of the disclosure.

A recombinant yeast cell functionally expressing: a) a nucleic acid sequence encoding a protein comprising phospho-ketolase (PKL) activity (EC 4.1.2.9 or EC 4.1.2.22) and / or a nucleic acid sequence encoding a protein having phosphotransacetylase (PTA) activity (EC 2.3.1.8) and / or a nucleic acid sequence encoding a protein having acetate kinase (ACK) activity (EC 2.7.2.12); and / or) a nucleic acid sequence encoding a protein having transketolase activity (EC 2.2.1.1), wherein the expression of the nucleic acid sequence encoding the protein having transketolase activity is under control of a promoter (the “TKL promoter”), which TKL promoter has an anaerobic / aerobic expression ratio for the transketolase of (2) or more.

A recombinant interleukin-27 (IL27) expressing virus is described. The recombinant IL27 expressing virus comprises an oncolytic virus comprising one or more exogenous nucleic acid sequences capable of expressing in IL27 protein or a biologically active portion thereof, the exogenous nucleic acid sequences being operably linked to an expression control sequence. Methods of treating cancer by in a subject by contacting a cancer cell of the subject with a recombinant IL27 expressing virus are also described.

The invention discloses a primer probe group, a kit and a detection method for detecting carbapenem drug resistance genes. Specifically, the primer probe group comprises primers with nucleotide sequences as shown in SEQ ID NO: 1-2, SEQ ID NO: 4-5, SEQ ID NO: 7-8, SEQ ID NO: 10-11 and SEQ ID NO: 13-14, and probes with nucleotide sequences as shown in SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12 and SEQ ID NO: 15. According to the present invention, the one-tube multi-detection can be achieved, the specific primer probe is optimized through the design and the multiple experiments, and the fluorescence PCR technology is adopted to simultaneously detect the five carbapenem antibiotic drug resistance genes such as KPC, NDM, IMP, VIM and OXA48-like in the one-tube reagent. The method has the advantages of simplicity and convenience in operation, high specificity and high sensitivity, and the lowest detection limit can reach 1CFU / PCR.

The invention discloses a sequence optimization method for balancing functions and yield. The sequence optimization method comprises the following steps: acquiring an initial amino acid sequence, a cell environment and a nucleic acid expression quantity; obtaining an initial nucleic acid sequence according to the initial amino acid sequence; obtaining a yield fraction through a preset yield module according to the initial nucleic acid sequence, the cell environment and the nucleic acid expression quantity; obtaining at least one function score through at least one preset function module according to the initial amino acid sequence; and simultaneously optimizing the initial amino acid sequence and the initial nucleic acid sequence through an optimization module according to the yield fraction and the at least one functional fraction to obtain an optimized amino acid sequence and an optimized nucleic acid sequence. According to the invention, the functional module and the yield module are integrated, and multi-objective optimization of protein sequences and corresponding nucleic acid sequences is realized through the optimization module.

The present invention provides for methods of epigenetic analysis. In some cases, the methods may include obtaining a sample comprising a nucleic acid sequence. In some cases, the nucleic acid sequence may comprise one or more epigenetic marks. The methods may include performing a sequencing. The methods may include distinguishing a hydroxymethylated base from a methylated base.

The present disclosure relates to a codon optimization technique based on token classification. In a model training phase, a collected protein sequence is tokenized by using a single amino acid as a token, and a nucleic acid sequence encoding a protein and corresponding to the protein sequence is tokenized by using a single codon as a token; a plurality of different synonymous codons in the tokenized nucleic acid sequence encoding the protein and corresponding to a single amino acid in the tokenized protein sequence are sorted in a descending order of frequency of occurrence in an expression system of the protein, and a classification label is set, thereby training a natural language model. In a prediction phase of the nucleic acid sequence encoding the protein, a protein sequence to be subjected to codon optimization is tokenized. The tokenized protein sequence is input into the trained natural language model to predict a classification label of a synonymous codon corresponding to a single amino acid in the tokenized protein sequence. An optimized nucleic acid sequence is obtained on the basis of a mapping relationship between the synonymous codon and the classification label thereof.

The present disclosure relates to a CCL20 promoter derived from a regulatory region of the CCL20 gene, which stimulates gene expression in response to inflammation. These CCL20 promoters, which can be stimulated by endogenous or exogenous cytokines, can be used to control the timing of expression of heterologous genes. The disclosure also relates to expression cassettes or vectors comprising a CCL20 promoter of the disclosure operably linked to a nucleic acid sequence encoding, for example, a polypeptide of interest; and delivery systems (e.g., viral particles, lipid vesicles or nanoparticles) or cells comprising such expression cassettes or vectors. The disclosure also relates to the use of the promoter, expression cassette, vector, delivery system or cell in the treatment of inflammation-related diseases or for recombinant gene expression.

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.

Provided are techniques for generating expression products using one or more nucleic acid concatemers that include tandem repeats of a nucleic acid sequence encoding the expression product or products. In one embodiment, different expression products may be co-expressed using a concatemer mixture of a first nucleic acid concatemer and a second nucleic acid concatemer having a predefined ratio to one another.

A recombinant yeast cell functionally expressing: a) a nucleic acid sequence encoding an enzyme having NADH-dependent nitrate reductase activity and / or a nucleic acid sequence encoding an enzyme having NADH-dependent nitrite reductase activity; and b) a nucleic acid sequence encoding a protein having transketolase activity (EC 2.2.1.1), wherein the expression of the nucleic acid sequence encoding the protein having transketolase activity is under control of a promoter (the “TKL promoter”), which TKL promoter has an anaerobic / aerobic expression ratio for the transketolase of 2 or more.

Methods and compositions for digital profiling of nucleic acid sequences present in a sample are provided.

The invention relates to a gene modified cell for producing HMOs, which can be applied to synthesis of difucosyllactose, and belongs to the technical field of gene engineering. The invention provides a genetically modified cell, which contains an alpha-1, 2-fucosyltransferase polypeptide and a heterologous nucleic acid sequence of the alpha-1, 3-fucosyltransferase polypeptide. The genetically modified cell has higher activity of synthesizing difucosyllactose, and does not contain synthetic 3-fucosyllactose or lower side activity of synthetic 2 '-fucosyllactose. The technical scheme of the invention has positive significance for industrial production of human milk oligosaccharide, and the method is green, efficient and sustainable, is beneficial to industrial large-scale production, and has important practical value.

Provided herein are fluorescently-labeled nucleotide conjugates for nucleic acid analysis. Also provided are reagents used for forming binding complexes between a fluorescently-labeled nucleotide conjugate and a target nucleic acid sequence in the presence of one or more reagents disclosed herein. Binding complexes can be detected in the presence of the one or more reagents. For example, the one or more reagents may contain a photobleaching reducing agent configured to reduce photobleaching resulting from use of the fluorescently-labeled nucleotide conjugate to form the binding complex in a nucleic acid analysis. Such nucleic acid analysis may be used to identify sites of nucleobase binding or incorporation between the target nucleic acid sequence and one or more nucleotide moieties of the fluorescently-labeled nucleotide conjugate in a nucleic acid sequence reaction.

The present invention includes a mutant Dnase1LS having at least about a 95% identity with a nucleic acid sequence encoding the protein of SEQ ID NO: 2-8 for a mutant Dnase1LS comprising at least one mutation for post-translational modification or attachment of a molecule to the mutant Dnase1LS to increase the serum half-life of the mutant Dnase1LS, nucleic acids encoding the same, host cells, and methods of making the mutant Dnase1LS.

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and / or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime / boost vaccination strategy.

Disclosed herein are nucleic acid compositions and methods of use. The nucleic acid compositions may have a therapeutic nucleic acid sequence operably linked to a nuclear targeting sequence that increases expression of the therapeutic nucleic acid in a cell by at least 1.25 fold; at least 80% sequence identity to SEQ ID NO: 6; or a first regulatory element comprising a promoter sequence operably linked to a hemoglobin subunit gamma intron (hBGi) sequence, and a second regulatory element comprising a woodchuck hepatitis posttranscriptional regulatory element (WPRE) sequence. The nucleic acid compositions with these features may enhance therapeutic nucleic acid transfection and expression. Also disclosed herein are transgenes optimized for gene therapy applications, including novel FVIII transgene sequences, in which the B domain may be non-naturally occurring the A1 and / or A3 domain may include at least one amino acid substitution.

Techniques are provided for generating an array-specific range of Tm values to be used for calling a sample in a given array positive or negative for a target nucleic acid sequence. A sample well in an array is provided with a control sample containing a control nucleic acid sequence. The control sample is amplified by thermal cycling the sample well. A Tm value for the control sample is identified and compared to an expected Tm value for the control nucleic acid sequence to calculate a relationship between the identified control Tm value and the expected control Tm value. By applying this relationship to an expected Tm value for a target nucleic acid sequence, an array-specific range of Tm values for the target nucleic acid sequence is generated and can be used for calling an experimental sample in the same array positive or negative for the target nucleic acid sequence.

The present disclosure provides methods, compositions and systems for detecting a nucleic acid sequence. In particular, detection oligonucleotides and detection polynucleotide complex configurations are described that can increase the complexity and multiplexing capabilities of an assay for detecting and decoding amplification products that correlate to multiple target molecules of interest from a sample.

The present invention provides a bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, the bacteriophage having a genome containing a nucleic acid sequence represented by the genome of the bacteriophage specified by the preservation number NITE BP-03513 or NITE BP-03514 or the preservation number NITE BP-03918, the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis, and the bacteriophage having a bacteriolytic activity against Mycobacterium avium and / or Mycobacterium intracellularis. The capsid of the phage is connected with the cell-penetrating peptide through a tag.

The utility model relates to the technical field of biological detection, in particular to a fluorescent PCR (Polymerase Chain Reaction) nucleic acid detection reagent strip for detecting Listeria monocytogenes, which is characterized in that after a sample to be detected is added into the reagent strip through a sample adding hole, the sample flows into a nucleic acid extraction area for nucleic acid extraction, and the extracted nucleic acid enters an amplification reaction area for amplification reaction; when a target nucleic acid sequence is amplified and then enters fluorescence detection to generate a fluorescence signal, a sensor in a fluorescence detection area captures the fluorescence signal in real time and transmits the signal to a control chip, the control chip processes and analyzes data, and a result is transmitted to external equipment (such as a computer, a mobile phone and the like) through a data transmission module. The rapid detection on the listeria monocytogenes is realized. The reagent strip disclosed by the utility model integrates the functions of nucleic acid extraction, amplification reaction and detection, is simple and convenient to operate, does not need complex sample pretreatment and professional experimental equipment, and is suitable for on-site rapid detection and basic application.

The invention belongs to the technical field of biomedical materials, and particularly relates to nucleic acid for synthesizing human III-type collagen as well as an in-vivo expression method and application of the nucleic acid. The nucleic acid sequence of the synthesized human III type collagen is as shown in SEQ ID NO. 1. The invention provides an effective mRNA (messenger ribonucleic acid) nucleic acid, the nucleic acid encodes a human full-length III-type collagen gene sequence, can effectively realize expression in a human body, and is guided to translate into full-length III-type collagen through the nucleic acid in human cytoplasm and has a correctly folded space structure triple-helix collagen, namely human III-type collagen.

The present invention relates to a method of producing cells having the phenotype of cardiac valve cells from precursor cells of valve cells comprising (a) introducing into said precursor cells early growth response 3 (EGR3) and / or a nucleic acid sequence encoding EGR3. The present invention also relates to a valve transplant comprising cells having the phenotype of valve cells obtained or obtainable by the method of the invention. The present invention furthermore relates to cells having the phenotype of valve cells obtained or obtainable by the method of the invention, the valve transplant of the invention or a compound promoting the expression and / or the activity of early growth response 3 (EGR3) for use in treating a subject having a valve defect.